|
Drug Interaction Study of Tegretol (Carbamazepine) and St. John's Wort in Normal Volunteers Clinical Trials Data presented on Clinical Trials Search is not meant to be a substitute for qualified medical advice, visits or professional assistance with a genuine dr.. We are not doctors. Always consult your mD about Drug Interaction Study of Tegretol (Carbamazepine) and St. John's Wort in Normal Volunteers conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Drug Interaction Study of Tegretol (Carbamazepine) and St. John's Wort in Normal Volunteers Clinical research trials and Drug Interaction Study of Tegretol (Carbamazepine) and St. John's Wort in Normal Volunteers medical trials take place in many of places throughout the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the effectiveness of new does drugs. The purpose of the studies / projects is to solve specific human healthcare questions. Clinical trials are a popular way for mDs, government agencies, and private sector companies to find cures for all varieties of conditions, like Drug Interaction Study of Tegretol (Carbamazepine) and St. John's Wort in Normal Volunteers. Drug Interaction Study of Tegretol (Carbamazepine) and St. John's Wort in Normal Volunteers Clinical Trials and other clinical trials allow for volunteers to have health treatment options before they are available to the masses. Many times the human subjects acquire professional assistance for free of charge, and sometimes they are compensated for their time. Occasionally there is a cost for a Drug Interaction Study of Tegretol (Carbamazepine) and St. John's Wort in Normal Volunteers clinical trial. Test subjects typically obtain the finest healthcare available for their Drug Interaction Study of Tegretol (Carbamazepine) and St. John's Wort in Normal Volunteers condition. Dangers are a reality, nevertheless, and might include additional or frequent doctor trips, medical dangers (possibly life-jeopardising), and/or the treatment being ineffectual. Trials are federally regulated with strict guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "D" Clinical Trials Conditions > Drug Interaction Study of Tegretol (Carbamazepine) and St. John's Wort in Normal Volunteers  Drug Interaction Study of Tegretol (Carbamazepine) and St. John's Wort in Normal Volunteers
Drug Interaction Study of Tegretol (Carbamazepine) and St. John's Wort in Normal Volunteers
For Condition: Healthy
Status: Completed
Sponsor(s): Warren G Magnuson Clinical Center (CC) ,
Synopsis: St. John's Wort is a popular dietary supplement that many patients-including those with epilepsy or seizures-take in addition to their regular medicines to elevate mood or relieve stress. Preliminary research indicates that this supplement can speed the metabolism of the anti-seizure drug Tegretol, causing reduced blood levels of the drug. Patients who take Tegretol to control their seizures may have more frequent seizures if the blood level of the drug drops too low. A recent study shows that this effect is not seen when Tegretol is taken for at least 3 weeks. The present study will examine whether there is a medically important drug interaction between St. John's wort and Tegretol when Tegretol is taken for 1 day. Normal healthy volunteers between 21 and 65 years old who are not taking medicines that can affect the metabolism of drugs in the liver and have not used St. John's wort for at least 30 days may be eligible for this 25-day study. Participants will take a 400-mg dose of Tegretol after fasting overnight. Blood samples will be drawn the next day during a 12-hour clinic stay at the following intervals: just before the Tegretol dose and at 1, 2, 4, 6, 8, 10, 24, 34, 48 and 72 hours after the dose. A catheter will be placed in the vein to prevent the need for multiple needle sticks until after the 10-hour sample. After completing the blood sampling, participants will take 300 mg of St. John's wort 3 times a day with meals for 2 weeks. After 2 weeks, another fasting dose of Tegretol will be given and the 72-hour blood study will be repeated. This study may provide information important for the care of patients with epilepsy who take both Tegretol and St. John's Wort.
Details: Alternative or complementary therapies are widely used by patients with epilepsy. St. John's Wort is one of the most popular herbal dietary supplements with a variety of claims including mood elevation and stabilization, stress relief, anti-viral effects, and enhancement of the immune system. We have previously demonstrated that treatment with St. John's Wort for 14 days does not induce the clearance of carbamazepine under steady state conditions of autoinduction of carbamazepine clearance. One proposed mechanism for this lack of effect is that St. John's Wort is not sufficiently potent to further induce previously induced CYP3A4 enzyme activity. The purpose of this study is to investigate the effect of St. John's Wort on single dose carbamazepine pharmacokinetics under conditions of uninduced CYP3A4. To evaluate this potential drug interaction, as well as the effect of St. John's Wort on epoxide hydrolase activity, eight normal healthy subjects will be enrolled into this pharmacokinetic study. Subjects will take a single 400 mg dose of carbamazepine followed by serial blood sampling over 72 hours for carbamazepine and carbamazepine epoxide plasma concentrations. Subjects will then begin taking a standardized formulation of St. John's Wort three times daily with meals for two weeks. Following 2 weeks of St. John's Wort subjects will then again take a single 400 mg dose of carbamazepine and have serial blood samples collected for carbamazepine and carbamazepine epoxide plasma concentrations. The total carbamazepine and carbamazepine epoxide exposure (AUC), oral clearance (CL/F), and maximal concentrations (Cmax) will be compared between treatment phases to characterize the potential drug interaction.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: Male or female. Healthy by medical history and physical exam. Age between 21 and 65 years old. Non-smoker for a minimum of 6 months. AST/SGOT less than or equal to 2 x upper limit of normal. Serum creatinine less than or equal to upper limit of normal. Hemoglobin greater than or equal to 10 g/dl. Females of childbearing potential must be using a reliable form of birth control other than hormonal contraceptives. No concomitant therapy with other inhibitors or inducers of cytochrome P-450 mediated drug metabolism within 30 days of study. No inability to remain free of chronic medications and alcohol for at least 2 weeks prior to and during the study. No previous use of St. John's Wort. Subjects with prior history of St. John's Wort use must abstain from use for 30 days prior to study participation. No presence of renal, hepatic, cardiovascular, hematologic, neurologic, psychiatric, or respiratory disease or any other condition that may interfere with the interpretation of the study results or not be in the best interests of the subject in the opinion of the investigator. No positive urine pregnancy test. No presence of persistent diarrhea or malabsorption that would interfere with the patients ability to adequately absorb drugs.
Total Enrollment: 12
Location and Contact Information:
Warren G. Magnuson Clinical Center (CC)
Bethesda, Maryland, 20892
United States
Additional Information:
Study ID Numbers: 010005; 01-CC-0005
Study Start Date: October 3, 2000
Record last reviewed: September 22, 2000
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00006395
Other Healthy Studies:
1. Magnetic Resonance Imaging for Evaluating Kidney Function
2. The Role of Cyclooxygenase Activity in the Endothelial Function of Hypertensive and Hypercholesterolemic Patients
3. Effect of Polyunsaturated Fatty Acids on Cardiovascular and Motor Responses Under Stress
4. Study of Thyrotropin-Releasing Hormone in Normal Volunteers and in Patients with Thyroid or Pituitary Abnormalities
5. Induction of Suction Blisters in Patients with Urticaria, Blistering Diseases, Inflammatory Dermatoses and Neoplastic Disorders, and in Normal Volunteers
Related Studies:
Other Healthy Clinical Trials
Other Maryland Clinical Trials
Other Bethesda Clinical Trials
Drug Interaction Study of Tegretol (Carbamazepine) and St. John's Wort in Normal Volunteers
|
|
|
|
|
|
|
|
